# Anti-malaria MAb in Malian Children

> **NCT05304611** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 365 (actual)

## Conditions studied

- Plasmodium Falciparum Infection
- Malaria

## Interventions

- **BIOLOGICAL:** L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
- **BIOLOGICAL:** L9LS (VRC-MALMAB0114-00-AB) intravenous injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05304611
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-18
- **Primary completion:** 2024-04-20
- **Final completion:** 2024-04-20
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304611, "Anti-malaria MAb in Malian Children". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05304611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*